Literature DB >> 11083664

Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species.

H F Geerdes-Fenge1, A Wiedersich, S Wagner, K H Lehr, P Koeppe, H Lode.   

Abstract

After oral administration of 500 mg of levofloxacin to 12 volunteers, we investigated the pharmacokinetics and serum bactericidal activities (SBAs) against five strains of members of the family Enterobacteriaceae. Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg. h/liter; elimination half-life 4.23 +/- 0.87 h. SBAs were present for 24 h against Escherichia coli and Citrobacter freundii. The SBAs at 1, 12, and 24 h after administration against E. coli were 1:108, 1:29, and 1:7, respectively, and those against Citrobacter freundii were 1:74, 1:25, and 1:7, respectively. The SBAs were present for 12 h against the other three organisms tested. The SBAs against Serratia marcescens were 1:28 and 1:9 at 1 and 12 h, respectively; the SBAs against Klebsiella pneumoniae were 1:25 and 1:7 at 1 and 12 h, respectively; and the SBAs against Enterobacter cloacae were 1:24 and 1:10 at 1 and 12 h, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083664      PMCID: PMC90229          DOI: 10.1128/AAC.44.12.3478-3480.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Authors:  S C Chien; A T Chow; J Natarajan; R R Williams; F A Wong; M C Rogge; R K Nayak
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

Review 3.  The clinical pharmacokinetics of levofloxacin.

Authors:  D N Fish; A T Chow
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

4.  In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

Authors:  T Fujimoto; S Mitsuhashi
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

5.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; M Corrado
Journal:  JAMA       Date:  1998-01-14       Impact factor: 56.272

Review 6.  Levofloxacin and sparfloxacin: new quinolone antibiotics.

Authors:  S J Martin; J M Meyer; S K Chuck; R Jung; C R Messick; S L Pendland
Journal:  Ann Pharmacother       Date:  1998-03       Impact factor: 3.154

7.  Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Authors:  S C Chien; M C Rogge; L G Gisclon; C Curtin; F Wong; J Natarajan; R R Williams; C L Fowler; W K Cheung; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 10.  Pharmacodynamics of fluoroquinolones.

Authors:  H Lode; K Borner; P Koeppe
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

View more
  4 in total

1.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.

Authors:  Liqin Zhu; Yuan Zhang; Jianwei Yang; Yongming Wang; Jianlei Zhang; Yuanyuan Zhao; Weilin Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-10       Impact factor: 2.441

2.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.

Authors:  Yongxin Zhao; Chunjiang Li; Jisheng Zhang; Yanjun Fu; Kewang Hu; Shanshan Su; Yong Wang; Huiling Li; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2019-12

4.  In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

Authors:  Luigi Principe; Silvia D'Arezzo; Alessandro Capone; Nicola Petrosillo; Paolo Visca
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-05-21       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.